Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ALT-P7 in HER2-Positive Metastatic Breast Cancer
NCT03281824Phase 1Completed
- Sponsor
- Alteogen
- Start
- Jan 2018
- Primary completion
- Mar 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALT-P7 in HER2-positive metastatic breast cancer, sponsored by Alteogen. Primary endpoint: Dose Limiting Toxicity at 21 days. Started Jan 2018; status: completed.
02
Drugs
ALT-P7
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT03281824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281824.